

From: OC GCP Questions
To: [REDACTED]
Subject: Clinical Study Reports (CSR)
Date: Monday, May 08, 2017 6:14:00 AM
Attachments: [REDACTED]

Good morning –

Sponsors often prepare a clinical study report for submission to regulatory agencies in marketing applications (e.g., a New Drug Application (NDA)). Such reports describe the objectives of the study, the study design, results from the study, and conclusions (among other things). The most complete guidance on the content of clinical study reports is found in the ICH E3, Structure and Content of Clinical Study Reports.

<https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073113.pdf>

It appears you are the sponsor and I assume the study was conducted under an IND. It is best to consult the regulatory project manager of the IND to see if a CSR is required.

Kind regards,

Doreen M. Kezer, MSN
Senior Health Policy Analyst
Office of Good Clinical Practice
Office of the Commissioner, FDA



This communication does not constitute a written advisory opinion under 21 CFR 10.85, but rather is an informal communication under 21 CFR 10.85(k) which represents the best judgment of the employee providing it. This information does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed.

From: [REDACTED]
Sent: Friday, May 05, 2017 3:52 PM
To: OC GCP Questions
Subject: Clinical Study Reports (CSR)

Good afternoon,

I hope my message finds you well.

I am reaching out to you today in order to receive bit of a clarity in regards to Clinical Study Report (CSR) requirement. Would you be so kind to let me know if Sponsor is required to submit CSR to the FDA if decision is made not to move forward with a marketing application?

Thank you so very much!
Have a lovely day and weekend!

Kind regards,
[REDACTED]